O

Oviva

Digital app delivering personalised dietary advice

Overview

Oviva is a health-tech platform that delivers personalised dietary advice through a digital app, supported by experienced coaches. Users subscribe to the app to receive tailored nutrition guidance and one-on-one coaching, with services designed for both individuals seeking health improvements and healthcare providers who refer patients. The product works by combining an app interface for tracking meals and progress with human coaching to guide targeted dietary changes aimed at long-term health. Oviva differentiates itself through its established position as a European leader in digital dietary advice, its integration with healthcare providers, and recognition from industry awards and high user recommendation rates. The goal is to help people prevent and manage illness through diet by making personalised nutrition guidance accessible and scalable across Europe.

Work here?Claim your company

About Oviva

Simplify's Rating
Why Oviva is rated
B+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

Consumer SoftwareHealthcare

Company Size

501-1,000

Company Stage

Series D

Total Funding

$351.6M

Headquarters

Zurich, Switzerland

Founded

2013

Get referred to Oviva

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Oviva closed a €200 million Series D on January 22, 2026.
  • Oviva achieved cash-flow profitability in 2025 and tripled new patient intake over two years.
  • Oviva added hypertension management in 2026, widening payer-covered chronic-care expansion.

What critics are saying

  • NICE granted Oviva conditional support in November 2026, demanding four years of extra evidence.
  • Germany's DiGA 2.0 raises evidence and interoperability requirements, increasing reimbursement and compliance risk.
  • Novo Nordisk and Kry launched a competing obesity program in Europe on November 6, 2026.

What makes Oviva unique

  • Oviva holds reimbursed programs in Germany, the UK, and Switzerland since January 2026.
  • Kinnevik called Oviva ten times larger than its closest competitor in February 2026.
  • Oviva has treated one million patients and published over 90 peer-reviewed studies.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$351.6M

Above

Industry Average

Funded Over

7 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
$80M
$100M
$234.2M

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

1%

1 year growth

21%

2 year growth

71%
myHSN
May 15th, 2026
Weight-loss jabs reduce sick days by 50%.

Weight-loss jabs reduce sick days by 50%. New research presented at the European Congress on Obesity by Martin Fidock and colleagues from Oviva reveals that weight-loss jabs could halve workplace sick days and free up millions of GP slots. By addressing obesity-related illnesses, these treatments significantly alleviate pressure on NHS primary care while boosting national productivity. Halving workplace absences. The study indicates that patients using GLP-1 receptor agonists saw their monthly sick leave reduced by approximately 50%, from an average of 2.41 days to 1.18 days. This shift offers a major economic boost, as obesity-related health issues currently drive a substantial portion of long-term disability and short-term leave across the workforce. Reducing GP workload. Data suggests that widespread access to these treatments could vacate millions of annual GP appointments. By mitigating comorbidities like hypertension and musculoskeletal pain, the number of patients requiring frequent health center visits dropped from 24.8% to 9.3%, allowing primary care providers to prioritise complex medical cases. Chronic disease mitigation. Obesity is a primary driver for numerous chronic conditions. The research highlights that pharmaceutical weight management leads to a decreased clinical need for the ongoing management of type 2 diabetes and cardiovascular issues, further streamlining healthcare delivery through a combination of injections and digital support. Socioeconomic ripple effects. Beyond direct health outcomes, the study underscores broader societal benefits. Improved physical health through medical intervention correlates with higher mental well-being and increased career longevity, which strengthens the labor market and reduces the £31 billion annual productivity drain attributed to obesity. Metabolic and clinical efficacy. The analysis suggests the benefits of these medications extend beyond simple appetite suppression. The metabolic improvements observed lead to sustained changes in energy processing, suggesting that the health gains achieved are more durable than those from traditional dieting alone. Implementation hurdles. Despite the benefits, the research addresses challenges regarding high drug costs and the necessity for strict clinical oversight. Success requires a strategic balance between the initial pharmaceutical investment and the long-term savings generated by a healthier, more active population. NHS transformation projections. If integrated into standard care, these treatments could transform the NHS landscape by 2030. Projections suggest a more agile service where preventative weight management becomes a central pillar of public health strategy, moving away from reactive emergency care. A proactive health paradigm. The findings advocate for treating obesity as a manageable chronic condition rather than a lifestyle choice. This shift allows the healthcare system to deploy resources more effectively, targeting the root causes of systemic health strain. Your feedback matters to MyHSN! How useful was this post? Click on a star to rate it! Average rating 5 / 5. Vote count: 2

De Tijd
Jan 22nd, 2026
AB InBev families and Boëls invest in British health app Oviva

Planet First, an investment fund backed by AB InBev families, has invested in British startup Oviva alongside Belgium's Boël family. Oviva develops apps for personalised diet and lifestyle advice. The investment amount and valuation were not disclosed in the available information.

MarketScreener
Jan 22nd, 2026
Kinnevik leads $220M Series D in Oviva, Europe's AI-enabled chronic care platform

Kinnevik has invested $100 million in Oviva as part of a $220 million Series D financing round, becoming the European digital healthcare company's largest shareholder. The investment makes Oviva one of Kinnevik's largest portfolio companies. Founded by Kai Eberhardt and Manuel Baumann, Oviva provides AI-enabled digital care for weight-related and chronic conditions across Germany, the UK and Switzerland. The company has supported over one million patients through fully reimbursed programmes and achieved cash-flow profitability in 2025. New patient intake has tripled over the past two years. The funding will support expansion into additional markets and chronic conditions including hypertension and type 2 diabetes, whilst advancing AI initiatives. Sofina and Temasek joined as new long-term investors alongside existing backers.

Startbase
Jan 22nd, 2026
Oviva closes €200 million Series D for AI-supported healthcare.

Oviva closes €200 million Series D for AI-supported healthcare. With one of the largest Series D rounds in Digital Health, Oviva aims to treat chronic diseases earlier, digitally, and scalably. Berlin-based digital health company Oviva has completed a Series D funding round of €200 million. The round consists of primary and secondary capital and is led by Kinnevik. Other investors include Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC, as well as existing investor Sofina. Oviva is a European provider of digital, reimbursable therapies for obesity and chronic diseases. This funding ranks among the largest growth rounds in the European digital health sector in recent years. Expansion into additional chronic indications planned. With the fresh capital, Oviva aims to expand its care offerings beyond obesity. Plans include expanding digital therapy programs for hypertension and type 2 diabetes to avoid or better treat costly subsequent conditions early on. Simultaneously, the company is investing in further developing its AI-supported platform, which offers patients personalized therapy pathways and supports medical professionals in daily treatment routines. Digital care against staff shortages and wait times. In Europe, over 200 million adults live with obesity, while access to long-term care is limited. Healthcare systems are increasingly struggling with staff shortages and long wait times. 'By supporting earlier and continuously accompanying patients, we prevent the progression of chronic diseases.' Kai Eberhardt, CEO and co-founder of Oviva According to Oviva, it addresses this gap with certified digital therapy programs that are fully reimbursed by health insurers and public healthcare systems in Germany, Switzerland, and the United Kingdom. Patients thus gain location-independent access to interdisciplinary care without months-long wait times. Particularly in the area of obesity therapies, we cannot necessarily understand these deficits in the German healthcare system, at least for qualified approaches by members of the DEG (German Society for Nutrition) and nutrition scientists. Nutritional consultation is still not a protected designation, and anything beyond simple dietary assistance should always be coordinated between nutrition scientists, physicians, and health insurers. This is very important, if only to recognize therapy-induced deficiencies early on and prevent them from arising in the first place. Over one million treated patients and scientifically proven. Since its founding in 2014, Oviva has treated more than one million patients. The effectiveness of the programs is supported by over 90 peer-reviewed studies. Over the past two years, the number of patients has tripled, and in 2025 the company achieved operational profitability. The platform combines an app certified as a medical device with human support through interdisciplinary treatment teams. AI ensures scalability, quality assurance, and efficiency. Long-term oriented investors with impact focus. With Kinnevik and the participating co-investors, the round brings together long-term oriented healthcare investors with a clear impact focus. The goal is to build a scalable care infrastructure that sustainably relieves Europe's healthcare systems.

StartupTicker
Jan 22nd, 2026
Digitalhealth company Oviva banks USD 200M Series D funding

Digitalhealth company Oviva banks USD 200M Series D funding. Oviva, a leading European provider of digital care for weight-related and chronic conditions, has secured USD 200M in a series D investment round led by Kinnevik with participation of various investors. This funding will be used to Oviva's scale evidence-based, personalized care to many more people. More than 200 million adults live with obesity and weight-related chronic conditions in Europe. Healthcare systems are strained. Significant clinician shortages and a lack of access to in-person care further exacerbate the issue. Kai Eberhardt and Manuel Baumann founded Oviva to address this challenge through an evidence-based, scalable, digital solution for chronic conditions well integrated within national reimbursement frameworks and physician workflows. Oviva offers a patient-facing interface with access to multidisciplinary care teams helping patients achieve sustainable, best-in-class outcomes. Its AI-enabled platform personalizes support for patients and allows clinicians to focus more on real patient impact and reaching more people. The programs are free of charge for patients given the company's full reimbursement status in its core markets: Germany, the UK, and Switzerland. To date, the company has supported more than one million patients to date and over the past two years, it has tripled new patient intake, and achieved cash-flow profitability in 2025, underscoring the scalability and durability of its product and business model. The effectiveness of Oviva's programs is also proven by over 90 peer-reviewed studies. Kinnevik led Oviva's USD 220m Series D round with a USD 100m investment, through a combination of primary and secondary capital. Kinnevik is now Oviva's largest shareholder, joining a strong group of new long-term investors and existing backers, among them Temasek and Sofina. Further participants in the series D round are Planet First Partners, A.P. Moller Holding, Lunate, EGS Beteiligungen AG, Norrsken VC. The financing will support Oviva in meeting growing demand, expanding into additional markets and chronic conditions such as high blood pressure and type 2 diabetes, as well as further advancing its AI-supported platform. Kinnevik's Senior Investment Director, Christian Scherrer, said, "Obesity is a multi-billion-dollar challenge which costs European countries more than 1.5% of GDP each year. This is where Oviva presents a rare win-win-win opportunity: better patient outcomes, meaningful time savings for physicians, and lower costs along with productivity gains for health systems. Oviva has found an incredibly strong product market fit. Kai and Manuel have impressed us with their clinical rigor, disciplined execution at scale, and a genuine commitment to impacting patients and health systems for the better. We look forward to partnering with the entire Oviva team to realize their vision of becoming the European leader in virtual chronic care."

Recently Posted Jobs

Sign up to get curated job recommendations

Oviva is Hiring for 31 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs